TY  - JOUR
AU  - Kutzsche, Janine
AU  - Schemmert, Sarah
AU  - Bujnicki, Tuyen
AU  - Zafiu, Christian
AU  - Halbgebauer, Steffen
AU  - Kraemer-Schulien, Victoria
AU  - Pils, Marlene
AU  - Blömeke, Lara
AU  - Post, Julia
AU  - Kulawik, Andreas
AU  - Jürgens, Dagmar
AU  - Rossberg, Wolfgang M.
AU  - Hümpel, Michael
AU  - Bannach, Oliver
AU  - Otto, Markus
AU  - Araujo, Joseph A.
AU  - Willuweit, Antje
AU  - Willbold, Dieter
TI  - Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs – A model of sporadic Alzheimer’s disease
JO  - Heliyon
VL  - 9
IS  - 8
SN  - 2405-8440
CY  - London [u.a.]
PB  - Elsevier
M1  - FZJ-2023-03523
SP  - e18443 -
PY  - 2023
AB  - Disease-modifying therapies to treat Alzheimer's disease (AD) are of fundamental interest for aging humans, societies, and health care systems. Predictable disease progression in transgenic AD models favors preclinical studies employing a preventive study design with an early pre-symptomatic treatment start, instead of assessing a truly curative approach with treatment starting after diagnosed disease onset. The aim of this study was to investigate the pharmacokinetic profile and efficacy of RD2 to enhance short-term memory and cognition in cognitively impaired aged Beagle dogs - a non-transgenic model of truly sporadic AD. RD2 has previously demonstrated pharmacodynamic efficacy in three different transgenic AD mouse models in three different laboratories. Here, we demonstrate that oral treatment with RD2 significantly reduced cognitive deficits in cognitively impaired aged Beagle dogs even beyond the treatment end, which suggests in combination with the treatment dependent CSF tau oligomer decrease a disease-modifying effect of RD2 treatment.
LB  - PUB:(DE-HGF)16
C6  - 37609390
UR  - <Go to ISI:>//WOS:001144588100001
DO  - DOI:10.1016/j.heliyon.2023.e18443
UR  - https://juser.fz-juelich.de/record/1014979
ER  -